Khanduri, U., & Sharma, A
Under pathological conditions, impaired cystine uptake depletes GSH, depriving GPX4 of essential reducing support and ultimately inducing ferroptosis
Functional and metabolic alterations of gut microbiota in children with new-onset type 1 diabetes
& Tan, B.K.H., 1997, Mechanisms of cardiovascular activity of Andrographis paniculata in the anaesthetized rat, Journal of Ethnopharmacology 56(2), 97101
FDA-approved pharmacotherapy alternatives include several options with established safety profiles: Semaglutide (Wegovy): A GLP-1 receptor agonist producing 12-15% weight loss, with cardiovascular benefits demonstrated in the SELECT trial and FDA-approved indication for reducing cardiovascular risk Liraglutide (Saxenda): A GLP-1 receptor agonist producing 5-8% weight loss [4] Phentermine-topiramate (Qsymia): FDA-approved combination producing 7-10% weight loss with established safety data Naltrexone-bupropion (Contrave): Combination targeting reward pathways and appetite, producing 5-9% weight loss [4] Orlistat (Xenical, Alli): Lipase inhibitor producing 3-5% weight loss with gastrointestinal side effects [4] Setmelanotide (Imcivree): For rare genetic obesity disorders (POMC, PCSK1, LEPR deficiency) [4] Metabolic and bariatric surgery should be considered for patients with BMI 40 kg/m or 35 kg/m with obesity-related comorbidities who have not achieved adequate weight loss with nonsurgical interventions
